Hemogenyx Pharmaceuticals Plc (LON:HEMO)

Market Cap	40.36M
Revenue (ttm)	n/a
Net Income (ttm)	-7.81M
Shares Out	6.04M
EPS (ttm)	-2.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,977
Average Volume	16,834
Open	662.00
Previous Close	668.00
Day's Range	640.00 - 700.00
52-Week Range	124.00 - 1,800.00
Beta	1.33
RSI	53.46
Earnings Date	Apr 23, 2026

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific anti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HEMO